In a clinical trial for HNSCC, patients treated with 1,25(OH)(2)D(3) had increased levels of CD4/8 (+)T lymphocytes in HNSCC tissue, which was associated with a better prognosis.[14] Therefore, increasing the vitality or infiltration level of CD4/8 (+)T lymphocytes is recommended to improve patient prognosis. The gene discussed is CD4; the disease is head and neck squamous cell carcinoma.